The printed and web-based components of the program are scheduled to debut in early summer. Live components of the program will debut in the fall. Biotechnological therapies, in many cases, offer an alternative and new course of treatment for patients with rheumatoid arthritis. With this specialized training, community pharmacists will be able to more effectively counsel their patients and monitor their medication therapies, leading to better outcomes. D., Manager of Corporate Accounts Marketing for Amgen.
Patients undergoing treatment with biotechnological drugs have special needs.
We believe this certificate program will enable community pharmacists to receive the training they need to help their patients with rheumatoid arthritis manage and control their disease with the assistance of biotechnological drugs. The National Institute for Pharmacist Care Outcomes, launched by NCPA in 1995, is the national accrediting organization for pharmacist care education and training programs leading to the pharmacist care Diplomate credential and a leading authority in helping community pharmacists develop new market niches in disease management. The nation's independent pharmacies, independent chains, and independent franchises employ more than 60,000 pharmacists and dispense nearly half of the nation's retail prescription medicines. National Community Pharmacists Association.